SI2628733T1 - Derivati acilbenzena - Google Patents

Derivati acilbenzena

Info

Publication number
SI2628733T1
SI2628733T1 SI201130404T SI201130404T SI2628733T1 SI 2628733 T1 SI2628733 T1 SI 2628733T1 SI 201130404 T SI201130404 T SI 201130404T SI 201130404 T SI201130404 T SI 201130404T SI 2628733 T1 SI2628733 T1 SI 2628733T1
Authority
SI
Slovenia
Prior art keywords
acylbenzene
derivative
acylbenzene derivative
Prior art date
Application number
SI201130404T
Other languages
English (en)
Inventor
Shigeo Yamanoi
Takahiro Katagiri
Hidenori Namiki
Madoka Hatta
Koji Matsumoto
Kanako Takahashi
Tomomi Yoshitomi
Yuichi Ochiai
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of SI2628733T1 publication Critical patent/SI2628733T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201130404T 2010-10-14 2011-10-13 Derivati acilbenzena SI2628733T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010231471 2010-10-14
JP2011022325 2011-02-04
EP11832583.6A EP2628733B1 (en) 2010-10-14 2011-10-13 Acylbenzene derivative
PCT/JP2011/073489 WO2012050151A1 (ja) 2010-10-14 2011-10-13 アシルベンゼン誘導体

Publications (1)

Publication Number Publication Date
SI2628733T1 true SI2628733T1 (sl) 2015-10-30

Family

ID=45938375

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130404T SI2628733T1 (sl) 2010-10-14 2011-10-13 Derivati acilbenzena

Country Status (27)

Country Link
US (1) US8722711B2 (sl)
EP (1) EP2628733B1 (sl)
JP (2) JP5069813B2 (sl)
KR (1) KR101829086B1 (sl)
CN (1) CN103249726B (sl)
AU (1) AU2011314712B2 (sl)
BR (1) BR112013009043B8 (sl)
CA (1) CA2814628C (sl)
CO (1) CO6771403A2 (sl)
CY (1) CY1116303T1 (sl)
DK (1) DK2628733T3 (sl)
ES (1) ES2532706T3 (sl)
HK (1) HK1185082A1 (sl)
HR (1) HRP20150225T1 (sl)
IL (1) IL225724A (sl)
MX (1) MX2013004176A (sl)
MY (1) MY160300A (sl)
NZ (1) NZ610145A (sl)
PL (1) PL2628733T3 (sl)
PT (1) PT2628733E (sl)
RS (1) RS53965B1 (sl)
RU (1) RU2585765C2 (sl)
SG (1) SG189320A1 (sl)
SI (1) SI2628733T1 (sl)
SM (1) SMT201500067B (sl)
TW (1) TWI487699B (sl)
WO (1) WO2012050151A1 (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006273B2 (en) 2011-07-29 2015-04-14 Daiichi Sankyo Company, Limited N-hetero-ring-substituted amide derivative
WO2013108800A1 (ja) 2012-01-18 2013-07-25 第一三共株式会社 置換フェニルアゾール誘導体
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
WO2017126524A1 (ja) * 2016-01-19 2017-07-27 第一三共株式会社 糖尿病治療剤の併用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
CN1281442A (zh) * 1997-10-06 2001-01-24 伊莱利利公司 用作神经保护剂的新颖化合物
ES2295200T3 (es) * 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2004303604B2 (en) 2003-12-24 2011-03-24 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
CA2646676A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
CA2770405C (en) 2009-08-05 2015-03-17 Daiichi Sankyo Company, Limited Sulfone derivative
MX2012001107A (es) 2009-08-05 2012-03-26 Daiichi Sankyo Co Ltd Derivado de amida.
GB201006166D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
ES2532706T3 (es) 2015-03-31
AU2011314712B2 (en) 2016-05-26
CN103249726A (zh) 2013-08-14
HRP20150225T1 (hr) 2015-06-19
CN103249726B (zh) 2015-01-07
JP5869985B2 (ja) 2016-02-24
DK2628733T3 (en) 2015-03-30
MX2013004176A (es) 2013-10-25
CA2814628C (en) 2015-06-16
CO6771403A2 (es) 2013-10-15
MY160300A (en) 2017-02-28
EP2628733B1 (en) 2014-12-24
RU2013121816A (ru) 2014-11-20
SG189320A1 (en) 2013-05-31
BR112013009043B1 (pt) 2019-06-18
KR101829086B1 (ko) 2018-02-13
EP2628733A1 (en) 2013-08-21
PL2628733T3 (pl) 2015-05-29
BR112013009043B8 (pt) 2019-09-17
US20130217733A1 (en) 2013-08-22
TWI487699B (zh) 2015-06-11
JP2012224640A (ja) 2012-11-15
IL225724A (en) 2015-10-29
BR112013009043A2 (pt) 2016-07-26
RS53965B1 (en) 2015-08-31
JP5069813B2 (ja) 2012-11-07
NZ610145A (en) 2015-02-27
HK1185082A1 (en) 2014-02-07
KR20130099094A (ko) 2013-09-05
US8722711B2 (en) 2014-05-13
AU2011314712A1 (en) 2013-05-02
CY1116303T1 (el) 2017-02-08
TW201305121A (zh) 2013-02-01
IL225724A0 (en) 2013-06-27
JPWO2012050151A1 (ja) 2014-02-24
SMT201500067B (it) 2015-05-05
CA2814628A1 (en) 2012-04-19
EP2628733A4 (en) 2014-02-26
WO2012050151A1 (ja) 2012-04-19
RU2585765C2 (ru) 2016-06-10
PT2628733E (pt) 2015-03-24

Similar Documents

Publication Publication Date Title
AP3607A (en) Substituted imidazopyridazines
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
HK1171452A1 (en) Substituted pyrrolidine-2-carboxamides -2-
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
ZA201300032B (en) Tetrahydrocarboline derivative
HK1188782A1 (en) Substituted sodium-1h-pyrazole-5-olate 1h--5-
HK1185082A1 (en) Acylbenzene derivative
EP2599775A4 (en) ETHINYLPYRAZOLDERIVAT
GB2490849B (en) Di-aspirin derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
HK1211281A1 (zh) -炔-維生素 衍生物
HUP1000243A2 (en) 8-hidroxy-quinoline derivatives
ZA201303887B (en) 2-carboxamide-4-piperazinyl-benzofuran derivative
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives